Thanks to a new technology, the diagnosis of brain cancer undergoes a breakthrough. The credit goes to cancer diagnostics company and University of Strathclyde Dxcover spin-out company. The company has indeed launched the liquid biopsy Dxcover, which was also effective in the early days of cancer growth, at a smaller volume and earlier stage.
There Research was published in the scientific journal Cancers.
Brain cancer: here are the advantages of the Dxcover liquid biopsy
According to Cancer Research UK, a 12,000 people in Britain are diagnosed with brain cancer each year and survival rates are 12% five years after diagnosis.